The increase in Aspergillus infections during and after the COVID-19 pandemic

Abstract

This paper aims to identify the correlation between Aspergillus infections and the COVID-19 pandemic. The literature review used PubMed, EBSCO, Proquest Central at Kırıkkale University, Google, and Google Scholar. Between 2024 and 1980, the keywords “Aspergillus," “aspergillosis,” “invasive pulmonary aspergillosis,” “IPA,” “COVID-19-associated pulmonary aspergillosis,” “CAPA,” and “COVID-19” were searched. An association between COVID-19 pneumonia and invasive pulmonary aspergillosis (IPA), a complication seen in patients with severe respiratory syndromes, has been recently demonstrated, and the clinical features of COVID-19-associated pulmonary aspergillosis (CAPA) have been detailed. Due to diagnostic delays and the quick deterioration of respiratory diseases, infections caused by the Aspergillus genus are frequently recognized after the fact, which is a sad reality. From direct angioinvasion to hypersensitivity reactions, Aspergillus may inflict various human diseases. Invasive Aspergillus infections are sporadic in immunocompetent people and nearly always affect those immunosuppressed due to lung illness, immunosuppressive medication, or immunodeficiency. Aspergillus fumigatus (A. fumigatus) was found in most COVID-19 patients, and CAPA was also detected in several of these individuals. Also, patients with severe respiratory illnesses, like influenza and MERS-CoV, have been found to have multiple instances of IPA as super-infections. The function of antifungal prophylaxis in CAPA is unknown even though A. fumigatus was detected before the start of CAPA. On the other hand, voriconazole medication may be effective if begun right after.

Keywords

• Aspergillus
• invasive pulmonary aspergillosis
• COVID-19 associated pulmonary aspergillosis
• COVID-19
• Aspergillus fumigatus

References

1. Trovato L, Calvo M, Migliorisi G, Astuto M, Oliveri F, Oliveri S. Fatal VAP-related pulmonary aspergillosis by Aspergillus niger in a positive COVID-19 patient. Respir Med Case Rep. 2021;32:101367. doi:10.1016/j.rmcr.2021.101367
2. Salmanton-García J, Sprute R, Stemler J, et al. COVID-19-Associated pulmonary aspergillosis, March-August 2020. Emerg Infect Dis. 2021; 27(4):1077-1086. doi:10.3201/eid2704.204895
3. Koehler P, Meis JF, Ostrosky-Zeichner L, et al. COVID-19/influenza-associated pulmonary aspergillosis—management. Uniklinik Köln: Köln, Germany, 2020. [cited 2020 May 30]. https://repository.publisso.de/resource/frl%3A6421494
4. Beer KD, Jackson BR, Chiller T, Verweij PE, Van de Veerdonk FL, Wauters J. Does pulmonary aspergillosis complicate coronavirus disease 2019? Crit Care Explor. 2020;2(9):e0211. doi:10.1097/CCE. 0000000000000211
5. Costantini C, van de Veerdonk FL, Romani L. Covid-19–associated pulmonary aspergillosis: the other side of the coin. Vaccines (Basel). 2020;8(4):713. doi:10.3390/vaccines8040713
6. Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19-associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi (Basel). 2020;6(2):91. doi:10.3390/jof6020091
7. van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020;202(1):132-135. doi:10.1164/rccm.202004-1038LE
8. Zhang SY, Lian JS, Hu JH, et al. Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty. 2020;9(1):85. doi:10. 1186/s40249-020-00710-6

9. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. Mycoses. 2020;63(8):766-770. doi:10.1111/myc.13135
10. Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020;26(12):1706-1708. doi: 10.1016/j.cmi.2020.07.010
11. lanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8(6):e48-e49. doi:10.1016/S2213-2600(20)30237-X
12. Harman EM. Aspergillosis. In: Soo Hoo GW (Ed). Medscape. Updated: May 12, 2021. https://emedicine.medscape.com/article/296052-overview#a5 (Accessed online on June 25, 2024)
13. Aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest. 1997;111(3):612-618. doi:10.1378/chest.111.3. 612
14. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170(6):621-625. doi:10.1164/rccm.200401-093OC
15. Rutsaert L, Steinfort N, Van Hunsel T, et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care. 2020;10(1):71. doi:10.1186/s13613-020-00686-4
16. Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis. 2021;73(11):e3606-e3614. doi:10.1093/cid/ciaa1065
17. Helleberg M, Steensen M, Arendrup MC. Invasive aspergillosis in patients with severe COVID-19 pneumonia. Clin Microbiol Infect. 2021; 27(1):147-148. doi:10.1016/j.cmi.2020.07.047
18. Mohamed A, Rogers TR, Talento AF. COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges. J Fungi (Basel). 2020;6(3):115. doi:10.3390/jof6030115
19. Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. Clin Microbiol Infect. 2020;26(12):1706-1708. doi: 10.1016/j.cmi.2020.07.010
20. Moeller B. Assessing invasive pulmonary aspergillosis incidence in COVID-19 vs Influenza. Pulmonary Advisor. Available at https://www.pulmonologyadvisor.com/home/topics/lung-infection/assessing-invasive-pulmonary-aspergillosis-incidence-in-covid-19-vs-influenza/. April 22, 2021.
21. Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): a comparison with influenza associated aspergillosis (IAPA). J Infect Dis. 2021;224(10):1631-1640. doi:10.1093/infdis/jiab163
22. Cennimo DJ. Coronavirus disease 2019 (COVID-19) clinical presentation. In: Bronze MS (Ed). Medscape. Updated: May 01, 2024.https://emedicine.medscape.com/article/2500114-clinical#b3 (Accessed online on June 25, 20214)
23. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782-793. doi:10. 1001/jama.2020.12839
24. CDC. Long-term effects of COVID-19. Centers for disease control and prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html. 2020 Nov 13; Accessed: December 1, 2021.
25. [Guideline] COVID-19 Treatment Guidelines Panel. Clinical Spectrum of SARS-CoV-2 Infection. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. March 1 2024 (updated); Accessed: February 29, 2024.
26. Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to sars-cov-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251-2252. doi:10.1001/jama.2020.22717
27. McFadyen JD, Stevens H, Peter K. The emerging threat of (Micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571-587. doi:10.1161/CIRCRESAHA.120.317447
28. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-360. doi:10.1086/525258
29. Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment. J Fungi (Basel). 2020;6(2):91. doi:10.3390/jof6020091
30. Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528-534. doi:10.1111/myc. 13096
31. Charles MP, Kali A, Easow JM, et al. Ventilator-associated pneumonia. Australas Med J. 2014;7(8):334-344. doi:10.4066/AMJ.2014. 2105
32. Torres A, Martin-Loeches I. Invasive pulmonary aspergillosis in ventilator-associated pneumonia: the hidden enemy? Am J Respir Crit Care Med. 2020;202(8):1071-1073. doi:10.1164/rccm.202006-2605ED
33. Person AK, Chudgar SM, Norton BL, Tong BC, Stout JE. Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. J Med Microbiol. 2010;59(Pt 7):834-838. doi:10.1099/jmm.0.018309-0
34. Trovato L, Scalia G, Domina M, Oliveri S. Environmental isolates of multi-azole-resistant Aspergillus spp. in Southern Italy. J Fungi (Basel). 2018;4(4):131. doi:10.3390/jof4040131
35. Dupont D, Menotti J, Turc J, et al. Pulmonary aspergillosis in critically ill patients with coronavirus disease 2019 (COVID-19). Med Mycol. 2021;59(1):110-114. doi:10.1093/mmy/myaa078
36. Schein F, Munoz-Pons H, Mahinc C, Grange R, Cathébras P, Flori P. Fatal aspergillosis complicating severe SARS-CoV-2 infection: a case report. J Mycol Med. 2020;30(4):101039. doi:10.1016/j.mycmed.2020.101039
37. Kitayama T, Tone K, Makimura K, Takagi M, Kuwano K. COVID-19-associated pulmonary aspergillosis complicated by severe coronavirus disease: is detection of Aspergillus in airway specimens before disease onset an indicator of antifungal prophylaxis? Cureus. 2023;15(3): e36212. doi:10.7759/cureus.36212
38. Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149-e162. doi:10.1016/S1473-3099(20)30847-1
39. Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review. J Hosp Infect. 2021;113:115-129. doi:10.1016/j.jhin.2021.04.012
40. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-1297. doi:10.1086/514341
41. Hatzl S, Reisinger AC, Posch F, et al. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Crit Care. 2021;25(1):335. doi:10.1186/s13054-021-03753-9